AK 01

Drug Profile

AK 01

Alternative Names: AK-01; Cell division inhibitors - AurKa Pharma; Erbumine; LY-3295668

Latest Information Update: 27 May 2017

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer AurKa Pharma
  • Class Antineoplastics
  • Mechanism of Action Cell division inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 17 May 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in Canada (PO) (NCT03092934)
  • 03 Apr 2017 AurKa Pharma plans a phase I/II trial for Solid tumours (Metastatic disease, Late-stage disease, Monotherapy, Second-line therapy or greater) in Canada (NCT03092934)
  • 19 Sep 2016 Preclinical trials in Solid tumours in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top